Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average): 2014-2025

Historic Shares Outstanding (Weighted Average) for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $174.0 million.

  • Ocular Therapeutix's Shares Outstanding (Weighted Average) rose 11.59% to $174.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.0 million, marking a year-over-year increase of 11.59%. This contributed to the annual value of $157.2 million for FY2024, which is 97.96% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Shares Outstanding (Weighted Average) of $174.0 million as of Q3 2025, which was up 9.23% from $159.3 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Shares Outstanding (Weighted Average) peaked at $174.0 million during Q3 2025, and registered a low of $76.3 million during Q1 2021.
  • In the last 3 years, Ocular Therapeutix's Shares Outstanding (Weighted Average) had a median value of $154.9 million in 2024 and averaged $129.3 million.
  • Data for Ocular Therapeutix's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 99.79% (in 2024) over the last 5 years.
  • Over the past 5 years, Ocular Therapeutix's Shares Outstanding (Weighted Average) (Quarterly) stood at $76.6 million in 2021, then increased by 1.17% to $77.5 million in 2022, then rose by 2.46% to $79.4 million in 2023, then surged by 97.96% to $157.2 million in 2024, then climbed by 11.59% to $174.0 million in 2025.
  • Its last three reported values are $174.0 million in Q3 2025, $159.3 million for Q2 2025, and $159.0 million during Q1 2025.